PainReform Ltd. (PRFX)

IL — Healthcare Sector
Peers: GSAC  IMCC  LIXT  MDIA  MTVA  NLSP  UPC  VRPX 

Automate Your Wheel Strategy on PRFX

With Tiblio's Option Bot, you can configure your own wheel strategy including PRFX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PRFX
  • Rev/Share 0.0
  • Book/Share -0.5885
  • PB -2.379
  • Debt/Equity -0.0289
  • CurrentRatio 0.6117
  • ROIC 9.5434

 

  • MktCap 2818396.0
  • FreeCF/Share -2.9226
  • PFCF -0.2781
  • PE -0.2742
  • Debt/Assets 0.019
  • DivYield 0
  • ROE -7.54

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
PRFX
Published: May 27, 2025 by: PRNewsWire
Sentiment: Neutral

As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel , May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ: PRFX).

Read More
image for news Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
PRFX
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation

Read More
image for news PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

About PainReform Ltd. (PRFX)

  • IPO Date 2020-09-01
  • Website https://www.painreform.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Ehud Geller
  • Employees 2
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.